FDA flags Ultra Bon after lab testing finds hidden diclofenac
The Food and Drug Administration is warning consumers not to purchase or use Ultra Bon, a product marketed for arthritis, pain, and osteoporosis on various websites, including eBay, and possibly in some retail stores. Laboratory analysis confirmed that the product contains diclofenac even though the ingredient is not listed on the label.
The finding raises a direct safety concern for anyone who may be taking the product as a seemingly harmless supplement or over-the-counter remedy. Diclofenac is a nonsteroidal anti-inflammatory drug, or NSAID, with well-known cardiovascular and gastrointestinal toxicity. When a drug is hidden inside a product sold outside the normal prescription and pharmacy channels, patients can be exposed without the usual safeguards that come with dose review, medication reconciliation, or counseling about interactions.
Hidden NSAID exposure can turn a routine pain product into a risk event
Diclofenac’s adverse effect profile is not theoretical. NSAIDs can increase the risk of serious heart problems, including heart attack and stroke, and they can also cause serious gastrointestinal injury such as bleeding, ulcers, or life-threatening tears in the stomach or intestinal lining. Those risks become even more consequential when the medication is undisclosed, because consumers cannot weigh the tradeoff between symptom relief and toxicity, and clinicians cannot account for the exposure when evaluating chest pain, anemia, melena, renal injury, or blood pressure changes.
A single hidden ingredient can collide with a patient’s entire medication list.
Because diclofenac can interact with other medications, especially other NSAID-containing products, the danger extends beyond one bottle of Ultra Bon. A person already using ibuprofen, naproxen, aspirin, anticoagulants, corticosteroids, or certain antihypertensive drugs may face amplified harm once an additional NSAID is introduced unknowingly. The practical consequence is straightforward: a product intended for joint pain may worsen the very cardiovascular and gastrointestinal conditions that often accompany chronic pain in older adults.
Why the label omission matters at the bedside
Clinicians rely on labeled ingredients to interpret side effects and counsel patients. When a product carries a false or incomplete label, the usual logic of adverse event assessment starts to break down. Unexplained stomach pain, black stools, vomiting blood, worsening edema, elevated blood pressure, or a sudden cardiovascular event may be misattributed unless the hidden NSAID exposure is recognized. In that setting, a patient may continue taking the product while symptoms escalate.
The risk profile is especially concerning for people with existing cardiovascular disease, peptic ulcer disease, kidney disease, or a history of NSAID sensitivity. Diclofenac is already an established prescription drug with known hazards; hidden exposure removes the clinician’s chance to screen for contraindications and monitor for toxicity. In older adults, where arthritis pain is common and polypharmacy is the rule rather than the exception, an undisclosed NSAID can destabilize a fragile balance very quickly.
FDA is directing consumers and clinicians to report adverse events
The agency is asking health care professionals and consumers to report adverse events or side effects related to Ultra Bon through FDA’s MedWatch Safety Information and Adverse Event Reporting Program. Reports can be submitted online through MedWatch or by fax using the downloadable form at 1-800-FDA-0178. Those reports matter because hidden-ingredient products often circulate through informal sales channels, making it harder to track where they are sold and who is exposed.
FDA also states that it cannot test and identify all products marketed as dietary supplements that contain potentially harmful hidden ingredients. That limitation leaves consumers to shoulder a large share of the risk recognition process, especially when products are promoted as natural solutions for pain relief or other health concerns. The agency’s warning is aimed not only at Ultra Bon itself but at the broader pattern of products marketed for sexual enhancement, weight loss, pain relief, and bodybuilding that may conceal pharmacologically active drugs.
A familiar fraud pattern in supplement marketing
Ultra Bon fits a recurring regulatory problem: products sold as supplements or conventional foods are sometimes represented as all natural while containing undisclosed drugs. In pain and arthritis products, a hidden NSAID can provide the illusion of effectiveness while exposing users to prescription-level adverse effects without prescription-level oversight. The concern is not merely mislabeled merchandise; it is unrecognized drug therapy delivered outside the clinical framework that normally governs safety.
For patients, the most immediate safeguard is caution before buying products that promise symptom relief through vague natural claims or through channels outside established pharmacy distribution. For clinicians, the immediate task is to ask about supplements and imported or online pain products when evaluating unexplained gastrointestinal bleeding, worsening hypertension, renal dysfunction, or cardiovascular events. A careful medication history can be the difference between a puzzling presentation and a clear toxic exposure.
The warning leaves one concrete unresolved issue: how many consumers have already been exposed before the product was identified, and how widely the same hidden ingredient pattern is circulating across similar pain products sold online.